Presentation

Company Profile
Integrum provides innovative systems for bone-anchored prostheses that have been improving the lives of people with amputations since 1990. The implant system has been proven in several clinical scientific studies and has been used by patients around the globe. Their technology is based on osseointegration, enabling the direct connection of an artificial limb to the skeleton. Several benefits, such as increased prosthetic use, improved mobility and enhanced quality of life, have been demonstrated. Their product, OPRA™ Implant System, has been used in over 500 surgeries, and it can be customised for one out of 5 different amputations: above elbow, below elbow, above knee, below knee, and thumb.

Recent highlights
During the last few Months, Integrum has been rapidly expanding their customer base, with several new hospitals and clinics introducing OPRA to their offering. In June 2021, Integrum completed a directed share issue of approximately 121 SEKm. The proceeds are intended to be used for: upscaling the company’s regulatory and reimbursement functions in order to accelerate adoption of the OPRA system in the US; continued investments in the sales, marketing and R&D departments; expansion of the product portfolio within EU and US with a focus on eOPRA and additional indications; development of R&D pipeline for next generation OPRA and eOPRA solutions.

Outlook
The company’s focus lies on continuing to develop their growth strategy, with the US being a primary attention point, and also to strengthen their market penetration though their cooperation with Onkos.